R&D trend #5: The top ex­ecs in biotech are rid­ing a boom — but there’s one big step left

Over the past few months I’ve been en­joy­ing watch­ing some se­r­i­al en­tre­pre­neurs dou­bling down on their ex­per­tise. Greg Ver­dine called re­cent­ly about his sec­ond on­go­ing start­up and launch round and Michael Gilman talked up his plans to hatch an­oth­er com­pa­ny as the first A round on his third biotech start­up was rolling out.

These days, drug de­vel­op­ment is more project ori­ent­ed than ever. Small teams un­der an ex­pe­ri­enced guid­ing hand can ac­com­plish a lot. They are tai­lor-made for nail­ing down proof-of-con­cept da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.